Tarsus Pharmaceuticals TARS
NASDAQ TARS
$90.78 +7.57 (+9.10%)
As of: Sep 4, 2026 · 3:59 PM EDT

Tarsus Pharmaceuticals (TARS) EBT Margin Growth (3y) (2024 - 2026)

Analysis

Tarsus Pharmaceuticals (TARS) EBT Margin Growth (3y) (2024 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -484.00
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 132.00
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 6,691.00
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -2,054.00
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 8,006.00
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 9,980.00
8 Royalty Pharma 28.45 Bn 27.61 Bn - -5,319.00
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 31,363.00
10 Tarsus Pharmaceuticals 3.96 Bn 3.51 Bn 161.80 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 93,093.00
Dec 31, 2025 13,215.00
Jun 30, 2025 1,614.00
Mar 31, 2025 364,837.00
Dec 31, 2024 423,624.00
Sep 30, 2024 121,708.00
Jun 30, 2024 -10,975.00
Mar 31, 2024 -16,081.00